Ibritumomab tiuxetan Y-90 consolidation a promising strategy in NHL

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1621, 2008-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibritumomab tiuxetan Y-90: Acute myeloid leukaemia in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1230, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90: Hepatitis B (first report) reactivation: case report

Reactions Weekly, Vol. 1, Iss. 1213, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Cytarabine/etoposide/ibritumomab tiuxetan Y-90: Treatment-related acute myeloid leukaemia?: case report

Reactions Weekly, Vol. 1, Iss. 1295, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90 plus high-dose BEAM chemotherapy was well tolerated in older patients with non-Hodgkin's lymphoma

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90: Pulmonary fibrosis (first report) in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1158, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite